^
Association details:
Evidence:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Go to data
Title:

Genetic and Molecular Mechanisms in Assessing Response in Patients With Prostate Cancer Receiving Enzalutamide Therapy

Excerpt:
...Androgen Receptor (AR) Messenger RNA (mRNA) Expression`Median AR-V7 expression between responders and non-responders.`...
Trial ID:
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Enzalutamide and Mifepristone in Treating Patients With Metastatic Hormone Resistant Prostate Cancer

Excerpt:
...Radiographic PFS`Number of Participants With Positive AR Expression Within Circulating Tumor Cells (CTCs)`Number of Participants With Positive GR Expression Within Circulating Tumor Cells (CTCs)`Testosterone`Thyroid Stimulating Hormone`Cortisol...
Trial ID:
Less C2 evidence
Evidence Level:
Resistant: C3 – Early Trials
Title:

Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance

Published date:
05/18/2020
Excerpt:
Levels of AR mRNA and protein expression were also similar between nonresponders and responders (Fig. 4B and SI Appendix, Table S2), suggesting that AR genomic changes or AR expression changes are not good predictors of enzalutamide response.
DOI:
https://doi.org/10.1073/pnas.1922207117
Trial ID: